{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:49:51Z","timestamp":1784731791498,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the lack of robust evidence of effectiveness, current treatment options for cancer-induced depression (CID) are limited to those developed for non-cancer related depression. Here, anhedonia-like and coping behaviours were assessed in female BALB\/c mice inoculated with 4T1 mammary carcinoma cells. The behavioural effects of orally administered sulfasalazine (SSZ), a system x<jats:sub>c<\/jats:sub><jats:sup>\u2212<\/jats:sup> inhibitor, were compared with fluoxetine (FLX). FLX and SSZ prevented the development of anhedonia-like behaviour on the sucrose preference test (SPT) and passive coping behaviour on the forced swim test (FST). The SSZ metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) exerted an effect on the SPT but not on the FST. Although 5-ASA is a known anti-inflammatory agent, neither treatment with SSZ nor 5-ASA\/SP prevented tumour-induced increases in serum levels of interleukin-1\u03b2 (IL-1\u03b2) and IL-6, which are indicated in depressive disorders. Thus, the observed antidepressant-like effect of SSZ may primarily be attributable to the intact form of the drug, which inhibits system x<jats:sub>c<\/jats:sub><jats:sup>\u2212<\/jats:sup>. This study represents the first attempt at targeting cancer cells as a therapeutic strategy for CID, rather than targeting downstream effects of tumour burden on the central nervous system. In doing so, we have also begun to characterize the molecular pathways of CID.<\/jats:p>","DOI":"10.1038\/srep41382","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T10:15:27Z","timestamp":1485339327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression"],"prefix":"10.1038","volume":"7","author":[{"given":"Mina G.","family":"Nashed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Ungard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Zacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Seidlitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Fazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benicio N.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurmit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"BFsrep41382_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/s1470-2045(11)70002-x","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell, A. J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. The Lancet. Oncology 12, 160\u2013174, doi: 10.1016\/s1470-2045(11)70002-x (2011).","journal-title":"The Lancet. Oncology"},{"key":"BFsrep41382_CR2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1017\/s0033291709992285","volume":"40","author":"M Pinquart","year":"2010","unstructured":"Pinquart, M. & Duberstein, P. R. Depression and cancer mortality: a meta-analysis. Psychological medicine 40, 1797\u20131810, doi: 10.1017\/s0033291709992285 (2010).","journal-title":"Psychological medicine"},{"key":"BFsrep41382_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/pon.3059","volume":"22","author":"S Brelin","year":"2013","unstructured":"Brelin, S. et al. Antidepressants to cancer patients during the last year of life--a population-based study. Psycho-oncology 22, 506\u2013514, doi: 10.1002\/pon.3059 (2013).","journal-title":"Psycho-oncology"},{"key":"BFsrep41382_CR4","doi-asserted-by":"crossref","unstructured":"Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C. & Hotopf, M. Antidepressants for the treatment of depression in people with cancer. The Cochrane database of systematic reviews 6, Cd011006, doi: 10.1002\/14651858.CD011006.pub2 (2015).","DOI":"10.1002\/14651858.CD011006.pub2"},{"key":"BFsrep41382_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/sj.bjc.6602949","volume":"94","author":"S Williams","year":"2006","unstructured":"Williams, S. & Dale, J. The effectiveness of treatment for depression\/depressive symptoms in adults with cancer: a systematic review. British journal of cancer 94, 372\u2013390, doi: 10.1038\/sj.bjc.6602949 (2006).","journal-title":"British journal of cancer"},{"key":"BFsrep41382_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00520-006-0145-3","volume":"15","author":"G Rodin","year":"2007","unstructured":"Rodin, G. et al. The treatment of depression in cancer patients: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 15, 123\u2013136, doi: 10.1007\/s00520-006-0145-3 (2007).","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"BFsrep41382_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2010.07.034","volume":"131","author":"CG Ng","year":"2011","unstructured":"Ng, C. G., Boks, M. P., Zainal, N. Z. & de Wit, N. J. The prevalence and pharmacotherapy of depression in cancer patients. Journal of affective disorders 131, 1\u20137, doi: 10.1016\/j.jad.2010.07.034 (2011).","journal-title":"Journal of affective disorders"},{"key":"BFsrep41382_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbr.2015.07.040","volume":"294","author":"MG Nashed","year":"2015","unstructured":"Nashed, M. G., Seidlitz, E. P., Frey, B. N. & Singh, G. Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression. Behavioural brain research 294, 25\u201335, doi: 10.1016\/j.bbr.2015.07.040 (2015).","journal-title":"Behavioural brain research"},{"key":"BFsrep41382_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.pnpbp.2006.03.036","volume":"30","author":"H Mitani","year":"2006","unstructured":"Mitani, H. et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Progress in neuro-psychopharmacology & biological psychiatry 30, 1155\u20131158, doi: 10.1016\/j.pnpbp.2006.03.036 (2006).","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"key":"BFsrep41382_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0006-3223(99)00159-6","volume":"47","author":"DP Auer","year":"2000","unstructured":"Auer, D. P. et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biological psychiatry 47, 305\u2013313 (2000).","journal-title":"Biological psychiatry"},{"key":"BFsrep41382_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/archpsyc.64.2.193","volume":"64","author":"G Hasler","year":"2007","unstructured":"Hasler, G. et al. Reduced prefrontal glutamate\/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of general psychiatry 64, 193\u2013200, doi: 10.1001\/archpsyc.64.2.193 (2007).","journal-title":"Archives of general psychiatry"},{"key":"BFsrep41382_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate, C. A. Jr. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of general psychiatry 63, 856\u2013864, doi: 10.1001\/archpsyc.63.8.856 (2006).","journal-title":"Archives of general psychiatry"},{"key":"BFsrep41382_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/clpt.2011.244","volume":"91","author":"JW Murrough","year":"2012","unstructured":"Murrough, J. W. Ketamine as a novel antidepressant: from synapse to behavior. Clinical pharmacology and therapeutics 91, 303\u2013309, doi: 10.1038\/clpt.2011.244 (2012).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"BFsrep41382_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959\u2013964, doi: 10.1126\/science.1190287 (2010).","journal-title":"Science"},{"key":"BFsrep41382_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/glia.21113","volume":"59","author":"J de Groot","year":"2011","unstructured":"de Groot, J. & Sontheimer, H. Glutamate and the biology of gliomas. Glia 59, 1181\u20131189, doi: 10.1002\/glia.21113 (2011).","journal-title":"Glia"},{"key":"BFsrep41382_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10585-009-9277-4","volume":"26","author":"EP Seidlitz","year":"2009","unstructured":"Seidlitz, E. P., Sharma, M. K., Saikali, Z., Ghert, M. & Singh, G. Cancer cell lines release glutamate into the extracellular environment. Clinical & experimental metastasis 26, 781\u2013787, doi: 10.1007\/s10585-009-9277-4 (2009).","journal-title":"Clinical & experimental metastasis"},{"key":"BFsrep41382_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbrc.2009.10.168","volume":"391","author":"MK Sharma","year":"2010","unstructured":"Sharma, M. K., Seidlitz, E. P. & Singh, G. Cancer cells release glutamate via the cystine\/glutamate antiporter. Biochemical and biophysical research communications 391, 91\u201395, doi: 10.1016\/j.bbrc.2009.10.168 (2010).","journal-title":"Biochemical and biophysical research communications"},{"key":"BFsrep41382_CR18","doi-asserted-by":"publisher","first-page":"1016s","DOI":"10.1093\/jn\/130.4.1016S","volume":"130","author":"QR Smith","year":"2000","unstructured":"Smith, Q. R. Transport of glutamate and other amino acids at the blood-brain barrier. The Journal of nutrition 130, 1016s\u20131022s (2000).","journal-title":"The Journal of nutrition"},{"key":"BFsrep41382_CR19","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1073\/pnas.0809130106","volume":"106","author":"BY Reddy","year":"2009","unstructured":"Reddy, B. Y., Greco, S. J., Patel, P. S., Trzaska, K. A. & Rameshwar, P. RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 106, 4408\u20134413, doi: 10.1073\/pnas.0809130106 (2009).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep41382_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jir.2014.0026","volume":"35","author":"M Esquivel-Velazquez","year":"2015","unstructured":"Esquivel-Velazquez, M. et al. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res 35, 1\u201316, doi: 10.1089\/jir.2014.0026 (2015).","journal-title":"J Interferon Cytokine Res"},{"key":"BFsrep41382_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ijc.28433","volume":"134","author":"PL Rodriguez","year":"2014","unstructured":"Rodriguez, P. L., Jiang, S., Fu, Y., Avraham, S. & Avraham, H. K. The proinflammatory peptide substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions. International journal of cancer . Journal international du cancer 134, 1034\u20131044, doi: 10.1002\/ijc.28433 (2014).","journal-title":"Journal international du cancer"},{"key":"BFsrep41382_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1096\/fj.09-141978","volume":"24","author":"J Huppert","year":"2010","unstructured":"Huppert, J. et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 1023\u20131034, doi: 10.1096\/fj.09-141978 (2010).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"BFsrep41382_CR23","doi-asserted-by":"publisher","first-page":"708306","DOI":"10.1155\/2015\/708306","volume":"2015","author":"JP Patel","year":"2015","unstructured":"Patel, J. P. & Frey, B. N. Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder? Neural Plast 2015, 708306, doi: 10.1155\/2015\/708306 (2015).","journal-title":"Neural Plast"},{"key":"BFsrep41382_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1042\/BST20140319","volume":"43","author":"KD Rochfort","year":"2015","unstructured":"Rochfort, K. D. & Cummins, P. M. The blood-brain barrier endothelium: a target for pro-inflammatory cytokines. Biochemical Society transactions 43, 702\u2013706, doi: 10.1042\/BST20140319 (2015).","journal-title":"Biochemical Society transactions"},{"key":"BFsrep41382_CR25","doi-asserted-by":"publisher","first-page":"e110024","DOI":"10.1371\/journal.pone.0110024","volume":"9","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Interleukin-1beta induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes. PloS one 9, e110024, doi: 10.1371\/journal.pone.0110024 (2014).","journal-title":"PloS one"},{"key":"BFsrep41382_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.neuroscience.2008.02.075","volume":"158","author":"VI Teichberg","year":"2009","unstructured":"Teichberg, V. I., Cohen-Kashi-Malina, K., Cooper, I. & Zlotnik, A. Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 158, 301\u2013308, doi: 10.1016\/j.neuroscience.2008.02.075 (2009).","journal-title":"Neuroscience"},{"key":"BFsrep41382_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pnpbp.2015.01.010","volume":"59C","author":"E Bentea","year":"2015","unstructured":"Bentea, E. et al. Absence of system xc- in mice decreases anxiety and depressive-like behavior without affecting sensorimotor function or spatial vision. Progress in neuro-psychopharmacology & biological psychiatry 59C, 49\u201358, doi: 10.1016\/j.pnpbp.2015.01.010 (2015).","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"key":"BFsrep41382_CR28","unstructured":"National Center for Biotechnology Information. PubChem Compound Database; CID=5384001, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5384001 (accessed Nov. 10, 2015)."},{"key":"BFsrep41382_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1517\/13543784.2012.670634","volume":"21","author":"H Sontheimer","year":"2012","unstructured":"Sontheimer, H. & Bridges, R. J. Sulfasalazine for brain cancer fits. Expert opinion on investigational drugs 21, 575\u2013578, doi: 10.1517\/13543784.2012.670634 (2012).","journal-title":"Expert opinion on investigational drugs"},{"key":"BFsrep41382_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/gut.49.6.783","volume":"49","author":"W Kruis","year":"2001","unstructured":"Kruis, W. et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 49, 783\u2013789 (2001).","journal-title":"Gut"},{"key":"BFsrep41382_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1139\/y09-129","volume":"88","author":"EP Seidlitz","year":"2010","unstructured":"Seidlitz, E. P., Sharma, M. K. & Singh, G. A by-product of glutathione production in cancer cells may cause disruption in bone metabolic processes. Canadian journal of physiology and pharmacology 88, 197\u2013203, doi: 10.1139\/y09-129 (2010).","journal-title":"Canadian journal of physiology and pharmacology"},{"key":"BFsrep41382_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00213-012-2926-3","volume":"226","author":"V Lutgen","year":"2013","unstructured":"Lutgen, V. et al. Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc(-) activity in the medial prefrontal cortex. Psychopharmacology 226, 531\u2013540, doi: 10.1007\/s00213-012-2926-3 (2013).","journal-title":"Psychopharmacology"},{"key":"BFsrep41382_CR33","doi-asserted-by":"publisher","first-page":"10514","DOI":"10.1523\/JNEUROSCI.3178-06.2006","volume":"26","author":"AY Shih","year":"2006","unstructured":"Shih, A. Y. et al. Cystine\/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. The Journal of neuroscience: the official journal of the Society for Neuroscience 26, 10514\u201310523, doi: 10.1523\/JNEUROSCI.3178-06.2006 (2006).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep41382_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbi.2010.12.010","volume":"25","author":"DM Lamkin","year":"2011","unstructured":"Lamkin, D. M. et al. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain, behavior, and immunity 25, 555\u2013564, doi: 10.1016\/j.bbi.2010.12.010 (2011).","journal-title":"Brain, behavior, and immunity"},{"key":"BFsrep41382_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3109\/10253890.2015.1083550","volume":"18","author":"RM Abuhamdah","year":"2015","unstructured":"Abuhamdah, R. M., Hussain, M. D., Chazot, P. L. & Ennaceur, A. Effects of chronic fluoxetine treatment on anxious behaviour of BALB\/c mice in a 3-dimensional maze. Stress (Amsterdam, Netherlands) 18, 677\u2013685, doi: 10.3109\/10253890.2015.1083550 (2015).","journal-title":"Stress (Amsterdam, Netherlands)"},{"key":"BFsrep41382_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.npp.1300433","volume":"29","author":"SC Dulawa","year":"2004","unstructured":"Dulawa, S. C., Holick, K. A., Gundersen, B. & Hen, R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 29, 1321\u20131330, doi: 10.1038\/sj.npp.1300433 (2004).","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"key":"BFsrep41382_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pain.2013.08.030","volume":"155","author":"RG Ungard","year":"2014","unstructured":"Ungard, R. G., Seidlitz, E. P. & Singh, G. Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. Pain 155, 28\u201336, doi: 10.1016\/j.pain.2013.08.030 (2014).","journal-title":"Pain"},{"key":"BFsrep41382_CR38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/BF00177926","volume":"92","author":"A Towell","year":"1987","unstructured":"Towell, A., Muscat, R. & Willner, P. Effects of pimozide on sucrose consumption and preference. Psychopharmacology 92, 262\u2013264 (1987).","journal-title":"Psychopharmacology"},{"key":"BFsrep41382_CR39","doi-asserted-by":"publisher","first-page":"e14458","DOI":"10.1371\/journal.pone.0014458","volume":"5","author":"BH Miller","year":"2010","unstructured":"Miller, B. H., Schultz, L. E., Gulati, A., Su, A. I. & Pletcher, M. T. Phenotypic characterization of a genetically diverse panel of mice for behavioral despair and anxiety. PloS one 5, e14458, doi: 10.1371\/journal.pone.0014458 (2010).","journal-title":"PloS one"},{"key":"BFsrep41382_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.metabol.2011.06.013","volume":"61","author":"MJ Park","year":"2012","unstructured":"Park, M. J., Yoo, S. W., Choe, B. S., Dantzer, R. & Freund, G. G. Acute hypoglycemia causes depressive-like behaviors in mice. Metabolism: clinical and experimental 61, 229\u2013236, doi: 10.1016\/j.metabol.2011.06.013 (2012).","journal-title":"Metabolism: clinical and experimental"},{"key":"BFsrep41382_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/pr800545q","volume":"8","author":"MK Tuck","year":"2009","unstructured":"Tuck, M. K. et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. Journal of proteome research 8, 113\u2013117, doi: 10.1021\/pr800545q (2009).","journal-title":"Journal of proteome research"},{"key":"BFsrep41382_CR42","doi-asserted-by":"crossref","unstructured":"Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Current protocols in immunology\/edited by John E. Coligan \u2026 [et al.] Chapter 20, Unit 20.22, doi: 10.1002\/0471142735.im2002s39 (2001).","DOI":"10.1002\/0471142735.im2002s39"},{"key":"BFsrep41382_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/00004714-200108000-00009","volume":"21","author":"I Gilaberte","year":"2001","unstructured":"Gilaberte, I. et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. Journal of clinical psychopharmacology 21, 417\u2013424 (2001).","journal-title":"Journal of clinical psychopharmacology"},{"key":"BFsrep41382_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejphar.2007.12.004","volume":"581","author":"K Horvath","year":"2008","unstructured":"Horvath, K. et al. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. European journal of pharmacology 581, 315\u2013323, doi: 10.1016\/j.ejphar.2007.12.004 (2008).","journal-title":"European journal of pharmacology"},{"key":"BFsrep41382_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1248\/bpb.25.264","volume":"25","author":"K Tokui","year":"2002","unstructured":"Tokui, K., Asai, Y., Arakawa, T., Matsumoto, T. & Nabeshima, T. Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. Biological & pharmaceutical bulletin 25, 264\u2013267 (2002).","journal-title":"Biological & pharmaceutical bulletin"},{"key":"BFsrep41382_CR46","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","volume":"71","author":"O Kohler","year":"2014","unstructured":"Kohler, O. et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71, 1381\u20131391, doi: 10.1001\/jamapsychiatry.2014.1611 (2014).","journal-title":"JAMA Psychiatry"},{"key":"BFsrep41382_CR47","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1038\/npp.2011.132","volume":"36","author":"J Hannestad","year":"2011","unstructured":"Hannestad, J., DellaGioia, N. & Bloch, M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 36, 2452\u20132459, doi: 10.1038\/npp.2011.132 (2011).","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"key":"BFsrep41382_CR48","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1523\/jneurosci.5258-04.2005","volume":"25","author":"WJ Chung","year":"2005","unstructured":"Chung, W. J. et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. The Journal of neuroscience: the official journal of the Society for Neuroscience 25, 7101\u20137110, doi: 10.1523\/jneurosci.5258-04.2005 (2005).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep41382_CR49","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1007\/s00213-014-3612-4","volume":"231","author":"V Lutgen","year":"2014","unstructured":"Lutgen, V. et al. Behavioral assessment of acute inhibition of system xc (-) in rats. Psychopharmacology 231, 4637\u20134647, doi: 10.1007\/s00213-014-3612-4 (2014).","journal-title":"Psychopharmacology"},{"key":"BFsrep41382_CR50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1471-4159.2009.06129.x","volume":"110","author":"WJ Chung","year":"2009","unstructured":"Chung, W. J. & Sontheimer, H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. Journal of neurochemistry 110, 182\u2013193, doi: 10.1111\/j.1471-4159.2009.06129.x (2009).","journal-title":"Journal of neurochemistry"},{"key":"BFsrep41382_CR51","doi-asserted-by":"publisher","first-page":"10041","DOI":"10.3390\/ijms130810041","volume":"13","author":"A Leibowitz","year":"2012","unstructured":"Leibowitz, A., Boyko, M., Shapira, Y. & Zlotnik, A. Blood glutamate scavenging: insight into neuroprotection. International journal of molecular sciences 13, 10041\u201310066, doi: 10.3390\/ijms130810041 (2012).","journal-title":"International journal of molecular sciences"},{"key":"BFsrep41382_CR52","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","volume":"15","author":"PW Gout","year":"2001","unstructured":"Gout, P. W., Buckley, A. R., Simms, C. R. & Bruchovsky, N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15, 1633\u20131640 (2001).","journal-title":"Leukemia"},{"key":"BFsrep41382_CR53","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1227\/neu.0000000000000080","volume":"73","author":"T Garzon-Muvdi","year":"2013","unstructured":"Garzon-Muvdi, T. et al. A glutamate receptor antagonist, S-4-carboxyphenylglycine (S-4-CPG), inhibits vasospasm after subarachnoid hemorrhage in haptoglobin 2-2 mice [corrected]. Neurosurgery 73, 719\u2013728; discussion 729, doi: 10.1227\/neu.0000000000000080 (2013).","journal-title":"Neurosurgery"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep41382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41382","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T21:14:01Z","timestamp":1671830041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep41382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,20]]}},"alternative-id":["BFsrep41382"],"URL":"https:\/\/doi.org\/10.1038\/srep41382","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]},"assertion":[{"value":"8 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BNF has received grant\/research support from Alternative Funding Plan Innovations Award, Brain & Behaviour Research Foundation, CIHR, Eli Lilly, Hamilton Health Sciences Foundation, J.P. Bickell Foundation, Ontario Brain Institute, Ontario Mental Health Foundation, Pfizer and Society for Women\u2019s Health Research, and has received consultant and\/or speaker fees from AstraZeneca, Bristol-Myers Squibb, Lundbeck, Pfizer, Servier and Sunovion. Other authors declare no competing financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41382"}}